This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: October 18th, 2011 - October 18th, 2012
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.
After completing this activity, the participant should be better able to:
- Describe optimal treatment options presented at the Annual Congress of the European Hematology Association (EHA) for patients with newly diagnosed MM
- Discuss the risks of developing secondary malignancies with novel MM treatments
- Describe current opinion on maintenance therapy for MM
- Discuss data on the optimal management of MM patients with renal dysfunction
- Summarize key clinical data presented at EHA on the use of novel agents in the treatment of relapsed/refractory MM
- Discuss data on the management of bone disease associated with MM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Edu cation (ACCME) through the joint sponsorship of Global
Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.25 contact hours.
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy edu cation. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-11-076-H01-P.
Disclosure of Conflicts of Interest
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships.
Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Kenneth C. Anderson, MD, is a consultant to BMS, Celgene, Merck, Millennium, Novartis, and Onyx. He is a founder of Acetylon Pharmaceuticals.
Paul Richardson, MD, serves on advisory boards for BMS, Celgene, Johnson & Johnson, Millennium, and Novartis.
Jesús F. San Miguel, MD, serves on advisory boards for and has received honoraria from Celgene, Janssen, Millennium, and Novartis.
Evangelos Terpos, MD, PhD, has received honoraria from Amgen, Janssen-Cilag and Novartis.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Karen Cooksey, Amanda Glazar, PhD, and Jackie Dawson, MSN, have nothing to disclose.
Lorrie McSherry, RN, BSN, OCN, is on an advisory board for Onyx.
Patricia Woster, PharmD, is a former employee of Eisai and has stock in Pfizer.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Medical Learning Institute do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Agenda: 1.25 hours
Articles/Commentaries: 60 minutes
Evaluation/Posttest: 15 minutes